Results 291 to 300 of about 825,078 (353)

Osteoclast‐Derived SLIT3 Mediates Osteoarthritis Pain and Degenerative Changes

Advanced Science, EarlyView.
In TMJ‐OA, osteoclasts play a significant role in promoting the growth of sensory nerves at the osteochondral interface. In early OA, TRAP+ osteoclast‐derived SLIT3 induces sensory nerve growth into the condylar cartilage. This nerve growth facilitates the development of pain associated with OA.
Weiwei Zhu, Wenpin Qin, Jialu Gao, Yihan Guo, Xiaoxiao Han, Zhangyu Ma, Xiaokang Zhang, Jie He, Jing Liu, Bo Gao, Changjun Li, Lina Niu, Jianfei Yan, Kai Jiao   +13 more
wiley   +1 more source

The Evolving Role of Second- and Third-Generation Tyrosine Kinase Inhibitors in Gastrointestinal Malignancies: Advances in Targeted Therapy with Sunitinib, Regorafenib, and Avapritinib. [PDF]

J Clin Med
Kawczak P, Bączek T.
europepmc   +1 more source

Weight, BSA, Toxicity, and Efficacy of Tyrosine Kinase Inhibitors for <i>ALK-</i>Mutated NSCLC. [PDF]

JTO Clin Res Rep
Munarriz BJ, Khan S, Hueniken K, Tam S, Patel D, Zhan L, Brown C, Eng L, Sacher A, Bradbury P, Leighl N, Liu G, Shepherd FA.   +12 more
europepmc   +1 more source

Third-Generation Bruton tyrosine kinase Inhibitors for the Treatment of Monoclonal Gammopathy of Thrombotic Significance (MGTS). [PDF]

Am J Hematol
Man L, Kanack AJ, Mauch EE, Splinter NP, Padmanabhan A.   +4 more
europepmc   +1 more source

Evaluation of Cardiotoxicity in Lymphoproliferative Patients Treated With Anthracycline and Bruton's Tyrosine Kinase Inhibitor-Based Regimens. [PDF]

Cureus
Bonsu A.
europepmc   +1 more source

Reigniting the Flame for Redifferentiation Strategies in Differentiated Thyroid Cancers: Journey of Tyrosine Kinase Inhibitors to Renewed Radioactive-Iodine Avidity. [PDF]

Endocrinol Metab (Seoul)
Oh JM, Zhu L, Ahn BC.
europepmc   +1 more source

Tyrosine kinase mutation.

Deutsches Arzteblatt international, 2010
openaire   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Tyrosine Kinase Inhibitors

Current Cancer Drug Targets, 2010
Over the last ten years, several new and therapeutically relevant cancer drugs targeting tyrosine kinases signaling pathways have been developed. Tyrosine kinase inhibitors (TKIs) are a pharmaceutical class of small molecules, orally available, well-tolerated, worldwide approved drugs for the treatment of several neoplasms, including lung, breast ...
NATOLI, Clara, Perrucci Bruno, Perrotti Francesca, Falchi Lorenzo, IACOBELLI, Stefano, Consorzio Interuniversitario Nazionale per Bio Oncologia   +5 more
openaire   +3 more sources